Hepatitis B Virus (HBV) Capsid Inhibitors Global Market Report 2025

Description

Hepatitis B virus (HBV) capsid inhibitors are antiviral agents designed to interfere with the assembly, disassembly, or stability of the viral capsid, which is crucial for HBV replication. These inhibitors act on the core protein that forms the protective shell around the viral DNA, thereby preventing the creation of new infectious particles. By disrupting the capsid formation process, they help lower viral load and slow disease progression. HBV capsid inhibitors represent a promising therapeutic strategy for moving toward a functional cure for chronic hepatitis B infection.

The main drug types of hepatitis B virus (HBV) capsid inhibitors include core protein allosteric modulators (CpAMs), capsid assembly modulators, and others. HBV capsid inhibitors, also known as core protein allosteric modulators (CpAMs), are antiviral agents that target and disrupt capsid assembly or stability, thereby blocking HBV replication and decreasing viral activity. The applications include chronic hepatitis B, acute hepatitis B, and other related uses, and they are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels. End users include hospitals, clinics, research institutes, and other healthcare settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The hepatitis B virus (HBV) capsid inhibitors market research report is one of a series of new reports from The Business Research Company that provides hepatitis B virus (HBV) capsid inhibitors market statistics, including hepatitis B virus (HBV) capsid inhibitors industry global market size, regional shares, competitors with a hepatitis B virus (HBV) capsid inhibitors market share, detailed hepatitis B virus (HBV) capsid inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis B virus (HBV) capsid inhibitors industry. This hepatitis B virus (HBV) capsid inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatitis B virus (HBV) capsid inhibitors market size has grown rapidly in recent years. It will grow from $0.46 billion in 2024 to $0.52 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period resulted from increasing clinical trials focused on HBV capsid assembly modulators, the rising inclusion of HBV in national immunization and health surveillance programs, growing publication of clinical data validating capsid inhibitor efficacy, heightened global awareness campaigns promoting HBV prevention and management, and the increasing adoption of advanced molecular modeling and drug design technologies.

The hepatitis B virus (HBV) capsid inhibitors market size is expected to see rapid growth in the next few years. It will grow to $0.86 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period will be driven by rising demand for combination therapies, an increasing number of pipeline products entering advanced clinical trial phases, higher patient awareness and screening rates for chronic HBV infection, growing adoption of personalized treatment approaches targeting viral resistance, and expanding use of digital platforms for clinical monitoring and treatment adherence. Major trends in the forecast period include the advancement of next-generation capsid assembly modulators progressing through clinical trials, development of advanced combination regimens pairing capsid inhibitors with immune modulators and cccDNA-targeting agents, innovative oral small-molecule formulations designed to improve patient adherence, integration of biomarkers and companion diagnostics to guide therapy selection, and progress in strategies for managing and preventing resistance, including next-generation molecules.

The rising prevalence of hepatitis B virus (HBV) infections is expected to drive the growth of the hepatitis B virus (HBV) capsid inhibitors market. Hepatitis B virus (HBV) infections are liver infections caused by the hepatitis B virus, which can lead to both acute and chronic diseases. The virus spreads through contact with infected blood or bodily fluids and can result in serious complications such as liver cirrhosis or liver cancer. The increasing prevalence of HBV infections is largely attributed to low vaccination coverage, leaving significant portions of the population unprotected and facilitating virus transmission. HBV capsid inhibitors aid in treating hepatitis B infections by disrupting the formation and assembly of the viral capsid, thereby preventing viral replication and reducing the spread of infection within the body. For example, in April 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that as of the end of 2022, only 13% of individuals with chronic hepatitis B had been diagnosed, and approximately 3% (7 million) had received antiviral treatment. In comparison, for hepatitis C, 36% of affected individuals had been diagnosed, with 20% (12.5 million) receiving curative therapy, figures well below the global target of treating 80% of people living with chronic hepatitis B and C by 2030. Therefore, the increasing prevalence of hepatitis B virus infections is driving the growth of the HBV capsid inhibitors market.

Major companies operating in the HBV capsid inhibitors market are focusing on developing advancements such as oral small-molecule capsid assembly modulators to improve antiviral efficacy, patient compliance, and achieve sustained viral suppression. Oral small-molecule capsid assembly modulators are orally administered antiviral agents that interfere with the assembly of the hepatitis B virus capsid, blocking replication and reducing viral activity in the body. For instance, in July 2024, Aligos Therapeutics, Inc., a US-based clinical-stage biopharmaceutical company, collaborated with Xiamen Amoytop Biotech Co., Ltd., a China-based biopharmaceutical company, to launch a clinical trial evaluating innovative treatment candidates for chronic hepatitis B (CHB). The trial leverages advanced capsid assembly modulator technology to enhance antiviral efficacy and accelerate the development of next-generation HBV therapies, marking a significant step in Aligos's mission to develop effective and potentially curative treatments for chronic hepatitis B patients.

In October 2023, Gilead Sciences Inc., a US-based biopharmaceutical company, partnered with Assembly Biosciences Inc. to combine its antiviral expertise with Assembly Biosciences' innovative capsid inhibitor technology. The collaboration aims to accelerate the development of next-generation small-molecule antivirals that enhance viral suppression, improve treatment outcomes, and potentially achieve a functional cure for patients living with chronic hepatitis B infection. Assembly Biosciences Inc., based in the US, specializes in the discovery and development of antiviral therapeutics, including novel agents targeting hepatitis B virus and other viral infections.

Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.

Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2024. The regions covered in hepatitis B virus (HBV) capsid inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hepatitis B virus (HBV) capsid inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hepatitis B virus (HBV) capsid inhibitors market consists of sales of vebicorvir, bepirovirsen, cavrotolimod, hepcludex, and morphothiadin. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatitis B Virus (HBV) Capsid Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatitis b virus (hbv) capsid inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatitis b virus (hbv) capsid inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hepatitis b virus (hbv) capsid inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Type: Core Protein Allosteric Modulators (CpAMs); Capsid Assembly Modulators; Other Drug Types
2) By Application: Chronic Hepatitis B; Acute Hepatitis B; Other Applications
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
4) By End-User: Hospitals; Clinics; Research Institutes; Other End-Users
Subsegments:
1) By Core Protein Allosteric Modulators (CpAMs): Class I Core Protein Allosteric Modulators (CpAMs); Class II Core Protein Allosteric Modulators (CpAMs)
2) By Capsid Assembly Modulators: Direct Capsid Assembly Modulators; Indirect Capsid Assembly Modulators
3) By Other Drug Types: Novel Capsid Inhibitors; Combination Therapies; Experimental Mechanism-Based Inhibitors
Companies Mentioned: Johnson & Johnson; Roche Holding AG; GlaxoSmithKline plc; Gilead Sciences Inc.; Jiangsu Hengrui Pharmaceuticals Co. Ltd.; Novotech Health Holdings Pte. Ltd; Enanta Pharmaceuticals Inc.; Assembly Biosciences Inc.; Arbutus Biopharma Corporation; Aligos Therapeutics Inc.; Qilu Pharmaceutical Co Ltd.; Chia Tai Tianqing Pharmaceutical Group Co Ltd.; Hepion Pharmaceuticals Inc.; Shanghai Zhimeng Biopharma Inc.; Antios Therapeutics; Bluejay Therapeutics Inc.; Core Biopharma Inc.; Door Pharmaceuticals; Shanghai Longwood Biopharmaceuticals Co. Ltd.; Zhimeng Biopharma Inc.
Countries:

Product Code: r40026

1. Executive Summary

2. Hepatitis B Virus (HBV) Capsid Inhibitors Market Characteristics

3. Hepatitis B Virus (HBV) Capsid Inhibitors Market Trends And Strategies

4. Hepatitis B Virus (HBV) Capsid Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Hepatitis B Virus (HBV) Capsid Inhibitors Growth Analysis And Strategic Analysis Framework

5.1. Global Hepatitis B Virus (HBV) Capsid Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market Growth Rate Analysis
5.4. Global Hepatitis B Virus (HBV) Capsid Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Hepatitis B Virus (HBV) Capsid Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Hepatitis B Virus (HBV) Capsid Inhibitors Total Addressable Market (TAM)

6. Hepatitis B Virus (HBV) Capsid Inhibitors Market Segmentation

6.1. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Core Protein Allosteric Modulators (CpAMs)
Capsid Assembly Modulators
Other Drug Types
6.2. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chronic Hepatitis B
Acute Hepatitis B
Other Applications
6.3. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
6.4. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Research Institutes
Other End-Users
6.5. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Sub-Segmentation Of Core Protein Allosteric Modulators (CpAMs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Class I Core Protein Allosteric Modulators (CpAMs)
Class II Core Protein Allosteric Modulators (CpAMs)
6.6. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Sub-Segmentation Of Capsid Assembly Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Direct Capsid Assembly Modulators
Indirect Capsid Assembly Modulators
6.7. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Novel Capsid Inhibitors
Combination Therapies
Experimental Mechanism-Based Inhibitors

7. Hepatitis B Virus (HBV) Capsid Inhibitors Market Regional And Country Analysis

7.1. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hepatitis B Virus (HBV) Capsid Inhibitors Market

8.1. Asia-Pacific Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hepatitis B Virus (HBV) Capsid Inhibitors Market

9.1. China Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
9.2. China Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hepatitis B Virus (HBV) Capsid Inhibitors Market

10.1. India Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hepatitis B Virus (HBV) Capsid Inhibitors Market

11.1. Japan Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
11.2. Japan Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hepatitis B Virus (HBV) Capsid Inhibitors Market

12.1. Australia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hepatitis B Virus (HBV) Capsid Inhibitors Market

13.1. Indonesia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hepatitis B Virus (HBV) Capsid Inhibitors Market

14.1. South Korea Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
14.2. South Korea Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market

15.1. Western Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
15.2. Western Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hepatitis B Virus (HBV) Capsid Inhibitors Market

16.1. UK Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hepatitis B Virus (HBV) Capsid Inhibitors Market

17.1. Germany Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hepatitis B Virus (HBV) Capsid Inhibitors Market

18.1. France Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hepatitis B Virus (HBV) Capsid Inhibitors Market

19.1. Italy Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hepatitis B Virus (HBV) Capsid Inhibitors Market

20.1. Spain Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market

21.1. Eastern Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
21.2. Eastern Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hepatitis B Virus (HBV) Capsid Inhibitors Market

22.1. Russia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hepatitis B Virus (HBV) Capsid Inhibitors Market

23.1. North America Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
23.2. North America Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hepatitis B Virus (HBV) Capsid Inhibitors Market

24.1. USA Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
24.2. USA Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hepatitis B Virus (HBV) Capsid Inhibitors Market

25.1. Canada Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
25.2. Canada Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hepatitis B Virus (HBV) Capsid Inhibitors Market

26.1. South America Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
26.2. South America Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hepatitis B Virus (HBV) Capsid Inhibitors Market

27.1. Brazil Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hepatitis B Virus (HBV) Capsid Inhibitors Market

28.1. Middle East Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
28.2. Middle East Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hepatitis B Virus (HBV) Capsid Inhibitors Market

29.1. Africa Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
29.2. Africa Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hepatitis B Virus (HBV) Capsid Inhibitors Market Competitive Landscape And Company Profiles

30.1. Hepatitis B Virus (HBV) Capsid Inhibitors Market Competitive Landscape
30.2. Hepatitis B Virus (HBV) Capsid Inhibitors Market Company Profiles
- 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Jiangsu Hengrui Pharmaceuticals Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Hepatitis B Virus (HBV) Capsid Inhibitors Market Other Major And Innovative Companies

31.1. Novotech Health Holdings Pte. Ltd
31.2. Enanta Pharmaceuticals Inc.
31.3. Assembly Biosciences Inc.
31.4. Arbutus Biopharma Corporation
31.5. Aligos Therapeutics Inc.
31.6. Qilu Pharmaceutical Co Ltd.
31.7. Chia Tai Tianqing Pharmaceutical Group Co Ltd.
31.8. Hepion Pharmaceuticals Inc.
31.9. Shanghai Zhimeng Biopharma Inc.
31.10. Antios Therapeutics
31.11. Bluejay Therapeutics Inc.
31.12. Core Biopharma Inc.
31.13. Door Pharmaceuticals
31.14. Shanghai Longwood Biopharmaceuticals Co. Ltd.
31.15. Zhimeng Biopharma Inc.

32. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hepatitis B Virus (HBV) Capsid Inhibitors Market

34. Recent Developments In The Hepatitis B Virus (HBV) Capsid Inhibitors Market

35. Hepatitis B Virus (HBV) Capsid Inhibitors Market High Potential Countries, Segments and Strategies

35.1 Hepatitis B Virus (HBV) Capsid Inhibitors Market In 2029 - Countries Offering Most New Opportunities
35.2 Hepatitis B Virus (HBV) Capsid Inhibitors Market In 2029 - Segments Offering Most New Opportunities
35.3 Hepatitis B Virus (HBV) Capsid Inhibitors Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer